Tata Institute’s Breakthrough: Developed Worth 100 Rupees Cancer Preventive Drug
Mumbai’s Tata Institute has made a huge step forward in cancer treatment by claiming to have discovered a revolutionary medication after ten years of intense research. The research aimed not just to treat cancer, but also to prevent it from returning.
Doctors and researchers at the Tata Institute have successfully developed a tablet that, when taken, is said to prevent cancer recurrence. Furthermore, this medication is intended to minimize the negative effects of radiation and chemotherapy by an astonishing 50%. The institute, which has committed the past decade to this research, is now preparing to make this revolutionary drug publicly available in the near future, for an unbelievable price of just Rs.100.
Senior oncologist Dr. Rajendra Badwe from Tata Memorial Hospital played a pivotal role in this groundbreaking research. The team utilized human cancer cells in mice for their studies. Following radiation therapy, chemotherapy, and surgery, the researchers observed the formation of ‘chromatin particles’ after cancer cells died. These particles, when transported through the bloodstream to other organs, were discovered to be possible causes of cancer recurrence. Some of these chromatin particles may also combine with healthy genes, resulting in cancerous forms.
To tackle this issue, the researchers gave the mice pre-oxidants including resveratrol and copper (R+CU). The combination of resveratrol and copper produces oxygen radicals, which efficiently destroy the chromatin particles. This novel technique not only prevents cancer recurrence but also reduces the adverse effects of chemotherapy.
Dr. Badwe expressed confidence in this innovative drug, underlining its potential to become the most economical cancer treatment at only Rs.100. The institute has submitted an application to the Food Safety and Standards Authority of India (FSSAI) for approval of this tablet, paving the way for a new era in cancer treatment accessibility and effectiveness.
